Question 1

What are the potential benefits of adding neoadjuvant chemotherapy to my treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer clinical trial (NCT01521702). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this trial compare to other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer clinical trial (NCT01521702). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from the neoadjuvant chemotherapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer clinical trial (NCT01521702). Contact the study team or your healthcare provider for specific answers.

Question 4

How will participating in this trial affect my overall treatment timeline?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer clinical trial (NCT01521702). Contact the study team or your healthcare provider for specific answers.

Question 5

What are the criteria for being eligible for this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer clinical trial (NCT01521702). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks associated with the neoadjuvant treatment that I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer clinical trial (NCT01521702). Contact the study team or your healthcare provider for specific answers.

What this study is about